PALISADE BIO INC (PALI)

US6963892046 - Common Stock

0.3991  +0 (+0.96%)

Fundamental Rating

3

Overall PALI gets a fundamental rating of 3 out of 10. We evaluated PALI against 203 industry peers in the Pharmaceuticals industry. PALI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PALI has a valuation in line with the averages, but on the other hand it scores bad on growth.



1

1. Profitability

1.1 Basic Checks

In the past year PALI was profitable.
PALI had a negative operating cash flow in the past year.
In the past 5 years PALI always reported negative net income.
In the past 5 years PALI always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -76.45%, PALI is doing worse than 71.14% of the companies in the same industry.
PALI's Return On Equity of -92.68% is in line compared to the rest of the industry. PALI outperforms 40.80% of its industry peers.
Industry RankSector Rank
ROA -76.45%
ROE -92.68%
ROIC N/A
ROA(3y)-142.65%
ROA(5y)-123.78%
ROE(3y)-214%
ROE(5y)-177.21%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PALI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

PALI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PALI has more shares outstanding
Compared to 1 year ago, PALI has an improved debt to assets ratio.

2.2 Solvency

PALI has an Altman-Z score of -10.38. This is a bad value and indicates that PALI is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -10.38, PALI is not doing good in the industry: 76.12% of the companies in the same industry are doing better.
There is no outstanding debt for PALI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.38
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

PALI has a Current Ratio of 6.14. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
PALI's Current ratio of 6.14 is fine compared to the rest of the industry. PALI outperforms 72.64% of its industry peers.
PALI has a Quick Ratio of 6.14. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PALI (6.14) is better than 73.13% of its industry peers.
Industry RankSector Rank
Current Ratio 6.14
Quick Ratio 6.14

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 126.11% over the past year.
EPS 1Y (TTM)126.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

PALI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.16% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.43%
EPS Next 2Y39.32%
EPS Next 3Y24.96%
EPS Next 5Y14.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.08, which indicates a rather cheap valuation of PALI.
100.00% of the companies in the same industry are more expensive than PALI, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.48, PALI is valued rather cheaply.
PALI is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 0.08
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PALI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PALI's earnings are expected to grow with 24.96% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y39.32%
EPS Next 3Y24.96%

0

5. Dividend

5.1 Amount

PALI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PALISADE BIO INC

NASDAQ:PALI (3/28/2024, 8:00:02 PM)

0.3991

+0 (+0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.84M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 0.08
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.45%
ROE -92.68%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.14
Quick Ratio 6.14
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)126.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y88.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y